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Background: Driven by high throughput next generation sequencing technologies and the pressing need to decipher
cancer genomes, computational approaches for detecting somatic single nucleotide variants (sSNVs) have undergone
dramatic improvements during the past 2 years. The recently developed tools typically compare a tumor sample
directly with a matched normal sample at each variant locus in order to increase the accuracy of sSNV calling. These
programs also address the detection of sSNVs at low allele frequencies, allowing for the study of tumor heterogeneity,
cancer subclones, and mutation evolution in cancer development.
Methods: We used whole genome sequencing (Illumina Genome Analyzer IIx platform) of a melanoma sample and
matched blood, whole exome sequencing (Illumina HiSeq 2000 platform) of 18 lung tumor-normal pairs and seven
lung cancer cell lines to evaluate six tools for sSNV detection: EBCall, JointSNVMix, MuTect, SomaticSniper, Strelka, and
VarScan 2, with a focus on MuTect and VarScan 2, two widely used publicly available software tools. Default/suggested
parameters were used to run these tools. The missense sSNVs detected in these samples were validated through PCR
and direct sequencing of genomic DNA from the samples. We also simulated 10 tumor-normal pairs to explore the
ability of these programs to detect low allelic-frequency sSNVs.
Results: Out of the 237 sSNVs successfully validated in our cancer samples, VarScan 2 and MuTect detected the most
of any tools (that is, 204 and 192, respectively). MuTect identified 11 more low-coverage validated sSNVs than VarScan
2, but missed 11 more sSNVs with alternate alleles in normal samples than VarScan 2. When examining the false calls of
each tool using 169 invalidated sSNVs, we observed >63% false calls detected in the lung cancer cell lines had alternate
alleles in normal samples. Additionally, from our simulation data, VarScan 2 identified more sSNVs than other tools,
while MuTect characterized most low allelic-fraction sSNVs.
Conclusions: Our study explored the typical false-positive and false-negative detections that arise from the use of
sSNV-calling tools. Our results suggest that despite recent progress, these tools have significant room for improvement,
especially in the discrimination of low coverage/allelic-frequency sSNVs and sSNVs with alternate alleles in normal
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Rapid advances in next generation sequencing (NGS)
technologies, together with the development of powerful
computational tools, have transformed biological and
biomedical research over the past several years. The
transformation has been most apparent in cancer, where
the complex landscapes of somatic variants have been
investigated in a wide variety of tumor types [1-3]. Most
significantly, a number of clinically actionable mutations
have been identified as important therapeutic targets in
anti-cancer treatments, narrowing the gap between basic
research and clinical application. Examples include
single nucleotide variants (SNVs) involving codons V600
and L597 in the gene BRAF in melanomas, which are
associated with sensitivity to BRAF and MEK inhibitors,
respectively [4,5].
A comprehensive knowledge of somatic variants in
cancer is indispensable for us to understand tumorigen-
esis and develop personalized therapies for patients.
However, although advances in next-generation sequen-
cing and computational algorithms have led to higher
accuracy in somatic SNV (sSNV) calling, some true
sSNVs are still difficult to distinguish due to low allele
frequencies, artifacts, tumor contamination, inadequate
sequencing coverage of genomic regions with high GC
content, sequencing errors, and ambiguities in short
read mapping, just to name a few. Another confounding
factor is clonal heterogeneity that causes variants to be
non-uniformly present in tumors [6,7]. Specifically, this
difficulty involves two aspects: false-negative sSNVs (true
sSNVs not called by the tools) and false-positive sSNVs
(spurious sSNVs, either germline SNVs or non-variants).
Somatic SNVs are identified by comparing a tumor
sample with a matched normal sample (usually blood
from the same patient). Originally, algorithms for identi-
fying sSNVs involved calling variants in the two samples
separately, for example, SNVMix [8]. To meet the chal-
lenges of sSNV calling, a number of tools with enhanced
accuracy have been developed that compare a tumor–
normal pair directly at each locus of a possible sSNV, for
example, JointSNVMix [9], SomaticSniper 1.0 [10], Strelka
[11], and VarScan 2 [12]. In comparison with previous







VarScan 2 2.3.5 http://varscan.sourceforge.net/
aDate: online/electronic publication date.from germline events, which vastly outnumber sSNVs and
thereby constitute the majority of false calls. Other
programs, such as MuTect [13] and EBCall [14], specific-
ally focus on detecting low-allelic-frequency sSNVs that
are often missed by existing tools.
Although each of the new tools has been compared
with some earlier applications, their relative merits in
real applications are largely unknown to investigators,
due to incomplete (and sometimes biased) experimental
evaluation. For example, the accuracy of MuTect was
not benchmarked against VarScan 2, a widely used
somatic variant-calling tool released a year earlier. To
provide a comparative analysis of sSNV-calling tools,
several review articles emerged lately [15,16]. However,
these reviews either lacked validation experiments [16]
or used only synthetic data [15], and hence are not
adequate to guide cancer genome sequencing studies.
Further evaluation of these tools’ capability is still
urgently required.
Here, we compare the abilities of the recently released
tools (Table 1), particularly MuTect and VarScan 2, to
detect sSNVs from NGS. We provide an in-depth
discussion of the pros and cons of each tool using vali-
dated NGS data, so that readers are aware of the kinds
of false-positive and false-negative results that may arise.
Furthermore, we use simulation data to analyze the




We used whole genome sequencing (WGS) of a melan-
oma sample and matched blood, whole exome sequen-
cing (WES) of 18 lung tumor-normal pairs and seven
lung cancer cell lines to evaluate SNV-calling tools.
The paired-end sequencing of the melanoma sample
(90% tumor content) and matched blood was performed
on an Illumina Genome Analyzer IIx platform as de-
scribed [5]. Average coverage was 55.7× and 47.8× for
the tumor and matched blood, respectively. From this
sample, our previous study identified 339,057 sSNVs
using SAMtools [17] pileup. As it is too expensive and
labor intensive to validate all those sSNVs, we selecteds (sSNVs) from next generation sequencing (NGS) data
Remark Datea Ref.
Uses an empirical Bayesian model to call sSNVs Mar. 2013 [14]
Joint analysis of tumor/normal pairs Jan. 2012 [9]
ct Sensitive detection of low allelic-fraction sSNVs Feb. 2013 [13]
r High computational efficiency Dec. 2011 [10]
Clean outputs through stringent filtering May 2012 [11]
Sensitive detection of high-quality sSNVs Feb. 2012 [12]
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and stopgain sSNVs, for experimental validation. For
each selected sSNV, PCR and direct sequencing was per-
formed using genomic DNA from the same tumor and
matched blood samples. The resulting sequences were
then analyzed using Mutation Surveyor DNA Variant
Analysis Software [18] in addition to manual inspection
of the sequence traces. The PCR primers used for direct
sequencing of sSNVs are publicly available through the
original work [5].
The whole exome data of the 18 lung tumors (approxi-
mately 70% to 80% tumor content) and matched normal
samples were captured using Agilent SureSelect 38 M
kit and sequenced on an Illumina HiSeq 2000 platform
as published [19]. On average, 48 Mb paired-end reads
were garnered per sample with an average sequencing
depth of 63× in target regions. Overall, the sequence
reads covered ≥98.9% bases of the target regions by at least
one read and ≥79.9% bases by a depth of at least 20×.
SAMtools was used to characterize sSNVs in these samples;
Sanger sequencing was utilized to validate functionally
important sSNVs. We have made the original sequence
data available at [20].
We also included NGS data from seven lung cancer
cell lines. Two of them, PC-9/S2 and PC-9/BRc1, were
sequenced on an Illumina HiSeq 2000 platform using
Nimblegen SeqCap Ez Exome Library kit v2 [21]. We
obtained 8.4 × 109 bases of short reads (74 bp paired-end)
for PC-9/S2 with an average of 232.6× coverage, and
7.8 × 109 bases of short reads for PC-9/BRc1 (216.7×
coverage) [21]. The other five cell lines, HCC827,
HCC827/R1, HCC827/R2, HCC4006, and HCC4006/ER,
were sequenced on an Illumina HiSeq 2000 platform
using the Agilent SureSelect 38 Mb kit for whole-exome
sequencing. Their average coverage is all >109×. For
these seven cell lines, the sequence reads covered ≥98.9%
bases of the target regions by at least one read and ≥85.5%
bases by a depth of at least 20×. Eight pairs of cell
lines were compared to identify sSNVs that were unique
to drug sensitivity or drug resistance cell lines (see
Additional file 1: Table S2). Specifically, the ‘somatic
model’ was executed by designating the targeted cell
line as ‘tumor’ and the cell line to be compared as ‘nor-
mal’. The sSNVs that resulted from the analysis were
then experimentally validated by Sanger resequencing.
Cell line DNAs were used as template for PCR amplifi-
cation. M13-tagged gene-specific primers were designed
using Primer 3 software [22]. Sequence chromatograms
were analyzed using Mutation Surveyor software [18]
and manual inspection. The details can be found in the
original work [21].
We also simulated WES of 10 tumor-normal pairs
using the profile-based Illumina pair-end Read Simulator
(pIRS) [23]. Our simulation procedure and correspondingcommand lines were described in detail in Additional file 2.
We fixed the insert size of the simulated reads at 200 bp.
The read length and average coverage were set to 75 bp
and 100×, respectively. Additionally, we let the frequency
of sSNVs in each sample be 10 times higher than that of
indels and structural variants be 10 times less than indels.
Because tumor samples carry driver mutations, we let the
frequency of SNVs in the tumor be higher than that in the
normal sample.
Alignment
We utilized BWA [24] to align short sequencing reads
to the UCSC human reference genome hg19. The de-
fault arguments of BWA were applied to the alignment.
After the alignment, we ran the software SAMtools [17]
to convert the alignment files to a sorted, indexed binary
alignment map (BAM) format. Then, we used Picard
[25] to mark duplicate reads. To obtain the best call set
possible, we also followed the best practice with the soft-
ware GATK [26] to do realignment and recalibration.
The recalibrated alignment files were then used for
sSNV detection.
SNV calling
JointSNVMix [9] uses a command ‘train’ to learn the
parameters of its probabilistic model. We let the argument
skip_size of ‘train’ be 100 for WES samples and 1,000 for
WGS samples to balance its accuracy and computational
efficiency. The command ‘classify’ in JointSNVMix com-
putes the posterior probability of joint genotypes. In our
experiments, we used a non-default argument post_pro-
cess, which was provided in the new version of Join-
tSNVMix, to run ‘classify’ to improve its filtering accuracy
[27]. The resulting sSNVs with P(somatic) >0.999 and post_-
process_p_somatic >0.6 are regarded as high confidence
sSNVs. The detailed command lines for the installation and
execution of JointSNVMix, as well as other sSNV-detecting
tools, are provided in Additional file 3.
MuTect [13], Strelka [11], and SomaticSniper [10]
were run in their default settings. dbSNP version 132
and COSMIC v54 were provided to MuTect as its
inputs. The sSNVs that were accepted by MuTect
were then used as its high confidence (HC) predic-
tions. To obtain SomaticSniper’s HC sSNVs, the out-
puts of SomaticSniper underwent a filtering procedure as
suggested by the tool developers. The recommended con-
figuration was also used to run VarScan 2 [12]. The high
confidence outputs of VarScan 2 were applied directly to
our analysis.
Results and discussion
We started with the melanoma tumor sample and its
matched normal sample (blood from the same individ-
ual) in order to examine the accuracy of the tools in
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tion of lung tumors and lung cancer cell lines. For these
samples, we restricted our discussion to validated sSNVs,
which include: (1) true-positive sSNVs: sSNVs predicted
by a tool and validated; (2) false-positive sSNVs: sSNVs
predicted but not validated; (3) false-negative sSNVs:
sSNVs not predicted but validated; and, (4) true-negative
sSNVs: sSNVs not predicted and not validated.
Detecting sSNVs in a melanoma sample
In our previous report on the melanoma sample,
339,057 sSNVs were detected; 1,130 were high-quality
non-synonymous/stop gain sSNVs (Phred quality >37,
depth >21) [5]. In total, 128 functionally important
sSNVs were validated, out of which 119 were true-
positive sSNVs and nine were false-positives. This sam-
ple harbors the aforementioned driver mutation BRAF
L597. We ran the six tools (EBCall, JointSNVMix,
MuTect, SomaticSniper, Strelka, and Varscan 2) on both
the melanoma and matched blood samples. With the ex-
ception of EBCall, all these tools successfully rediscov-
ered the BRAF L597 mutation.
Table 2 summarizes the results of analyses using these
tools. Because they (except EBCall) detected a similar
amount of sSNVs from the data, to simplify our assess-
ment, we directly compared each tool’s number of true-
positive predictions. As shown in Table 2, VarScan 2 had
the highest true-positive rate, missing only one sSNV (at
chr19:40886706) in its high confidence (HC) setting.
This missed sSNV was detected by VarScan 2 initially. It
was filtered out later by VarScan 2 due to a significant
amount of mismatches flanking the mutated site. Aside
from VarScan 2, other tools did not report this specific
sSNV either.
MuTect had the second best performance, missing
four real sSNVs (Table 2). The reasons that MuTect
rejected these sSNVs were various, including ‘nearby gap
events’ and ‘alternate allele in normal’, among others. For
the sSNV rejected for ‘alternate allele in normal’, only
one out of 42 (2.4%) reads was actually altered at this
site in the blood sample, indicating the stringent filtering
strategy of MuTect. At this site in the tumor, 21 (28%)Table 2 Number of validated true/false sSNVs detected
using the five tools in a melanoma sample
Tool All sSNVs High confidence sSNVs
# TP # FP # TP # FP
JointSNVMix 119 2 108 0
MuTect 119 9 115 0
SomaticSniper 116 4 104 0
Strelka 117 0 113 0
Varscan 2 119 6 118 2
FP: false-positive sSNVs; TP: true-positive sSNVs.out of 75 reads support this somatic event (9 on the for-
ward strand and 12 on the reverse), exhibiting strong
evidence for its existence. In addition to MuTect, Join-
tSNVMix and SomaticSniper also missed this sSNV,
while VarScan 2, together with Strelka, correctly re-
ported it (see Additional file 1: Table S1).
The alternate allele for a somatic SNV is observed in
the normal sample typically as a result of sample con-
tamination, for example, circulating tumor cells in blood,
normal tissue contaminated with adjacent tumor. Se-
quencing error and misalignment can also contribute
false mutation-supporting reads to the normal. Because
sample contamination is hard to prevent during sample
preparation step, it is important for an sSNV-calling tool
to tolerate to some extent the presence of low level mu-
tation allele in normal sample in order not to miss au-
thentic sSNVs. Hence, while using a tool less tolerant to
alternate allele in the normal, for example, MuTect, re-
searchers are advised to check the sSNVs rejected for
alternate allele in the normal, especially when characteriz-
ing sSNVs from low purity samples.
Table 2 also shows that VarScan 2 reported two false-
positive sSNVs (at chr6:128294851 and chr19:7141752,
respectively). Both sSNVs exhibited stand bias, that is,
their mutated bases are present in only one allele. Due
to the importance of strand bias, we leave the in-depth
discussion of this topic to the next section.
It may be worth mentioning that EBCall, as shown in
Table 1, uses a set of normal samples to estimate se-
quencing errors with which to infer the discrepancy be-
tween the observed allele frequencies and expected
errors. Although this design might improve sSNV calling
[14], a potential problem is that unmatched error distri-
bution between normal references and target samples
can adversely affect variant calling. If investigators do
not have normal references with the same/similar error
rate as the target tumors, this strategy inevitably fails.
This may explain our experimental observations, in
which EBCall (in its default setting) failed to identify the
majority of sSNVs despite the fact that the normal refer-
ences we used were sequenced from the same Illumina
platform as the tumors. Due to its lower-than-expected
accuracy, we therefore excluded EBCall from Table 2,
and, hereafter, we did not include EBCall in our
comparison.
Identifying sSNVs in lung tumors and lung cancer cell lines
Next, we evaluated the five tools using WES data of 18
lung tumor-normal pairs [19] and seven lung cancer cell
lines [21]. For these 43 WES samples, 118 putative
sSNVs were validated as true-positives. The majority of
these sSNVs had decent coverage in both tumor and
normal samples, while 26 of them (all from the 18 lung
tumors) were covered by <8 reads in the normal samples
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Of note, here we used the default read-depth cutoff of
VarScan 2, that is, eight in the normal samples, to de-
note an sSNV as either high or low quality.
For these WES samples, 64% (59 out of 92) high-
quality validated sSNVs were reported by all the five
tools, less than the 82% of the sSNVs that they shared
on the melanoma sample. Among the five tools, VarScan
2 identified the most high-quality sSNVs (Table 3). For
characterization of low quality ones, however, VarScan 2
was inferior to the other tools primarily due to its strin-
gent read-depth cutoffs and our application of its high-
confidence setting in this study. MuTect detected the
most low-quality sSNVs, but at a cost of an elevated false
positive rate, as indicated in column 3 of Table 3. For the
sSNVs missed by MuTect but identified by VarScan 2, 10
out of 14 (7 from the lung tumors, another 7 from the
lung cancer cell lines) had support reads in the normal
samples. This result confirmed our previous observation
that MuTect appeared to be more conservative than
VarScan 2 in reporting sSNVs with alternate alleles in
the normal samples.
For these 43 WES samples, 160 putative sSNVs were
false-positives. The large number of false-positive sSNVs
of these data allowed us to examine the typical false calls
of these tools. Table 3 shows that overall these tools had
similar false detection rates. Additionally, as a result of a
preference to detect more sSNVs in higher coverage
data, Varscan 2 called 13 false-positive sSNVs in the
seven lung cancer cell lines, more than MuTect and
other tools. Varscan 2’s tendency to call more sSNVs in
higher quality data was also manifested on the 18 lung
tumors, where it also characterized more high quality
sSNVs than other tools. Nine (69%) out of the 13 false
calls by Varscan 2 from the seven cell lines have alter-
nate alleles in the normal samples. Similarly, the major-
ity (>63%) of false-positive sSNVs detected by the other
four tools from the seven cell lines have support reads in
the normal (see Additional file 1: Table S2), indicating
that the challenge to discriminate sSNVs with alternate
alleles in normal samples remains to be illuminated.Table 3 Number of validated true/false sSNVs detected using
Tool Lung tumors (n = 18) Lung cancer
TP FP
# High quality # Low quality # High quali
JointSNVMix 30 17 6 49
MuTect 30 19 11 47
SomaticSniper 33 17 10 47
Strelka 27 17 8 51
Varscan 2 35 8 5 51
aTotal is the sum of #sSNVs found in lung tumors and lung cancer cell lines.
FP: false-positive sSNVs; TP: true-positive sSNVs.As demonstrated in the section above, when calling
sSNVs, another potential source of false-positives is
strand bias. Here, we specifically call an sSNV whose al-
ternate alleles all come from one strand a strand-biased
sSNV. The phenomenon of stand bias is common with
Illumina sequencing data. For example, among the nine
false sSNVs validated for the melanoma sample, six ex-
hibited strand bias. The discrimination of strand-biased
sSNVs from artifacts is another current challenge. Some
tools, for example, Strelka, discard strand-biased sSNVs,
especially those of low quality, so that investigators do
not waste resources on validating potential wild-type
mutations. Another strategy used in many tools, for ex-
ample, VarScan 2 and MuTect, is to keep them for
users to decide whether to keep or discard. MuTect im-
plemented a strand-bias filter to stratify reads by direc-
tion and then detect SNVs in the two datasets
separately. This filter allows MuTect to reject spurious
sSNVs with unbalanced strands effectively. From our
lung cancer and melanoma samples, MuTect identified
four strand-biased sSNVs in total, VarScan 2 reported
five, and none was found by Strelka. The number of
false-positive sSNVs among these detections was 1 and
2 for MuTect and VarScan 2, respectively. For the two
aforementioned false-positives identified by VarScan 2 in
the melanoma sample, the reads supporting the refer-
ence allele were highly biased to the forward strand
(one SNV: 22+/3-; another: 21+/2-), while the reads
supporting the alternate allele were all biased to the re-
verse (one: 0+/11-; another: 0+/10-) , hence indicating a
sign of duplicity. MuTect successfully filtered out both
false-positives.
As shown in Table 3, from the 18 lung tumors,
MuTect reported a total of 11 false-positive sSNVs, the
most among the five tools. Among these false-positive
detections, two were not reported by other tools, and
were thus unique to MuTect (see Additional file 4:
Figure S1). One of these two MuTect-specific sSNVs
exhibited strand bias in addition to a low coverage in
the normal sample, while the other had low coverage
in both tumor and normal samples.the five tools in the lung cancer samples
cell lines (n = 7) Totala
TP FP TP FP
ty # Low quality # High quality # Low quality
0 11 79 17 17
0 7 77 19 18
0 9 80 17 19
0 10 78 17 18
0 13 86 8 18
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Due to cost, researchers often choose only a small subset
of high-quality and functionally important sSNVs for
experimental validation. As a result, publicly available
validation results of low allelic-frequency sSNVs are rare.
With the lack of experimental data, here, we used simu-
lation data instead to evaluate these tools’ capabilities to
identify sSNVs at different allele fractions.
We simulated 10 pairs of whole exome sequencing
samples at coverage of 100× (see Additional file 2).
Then, we ran the tools (listed in Table 1) to identify
sSNVs from these data. Because few sSNVs within the
captured regions were at low allele fractions (approxi-
mately 1% with allele frequency <0.15), we utilized all
high quality sSNVs, both inside and outside the target
regions, to evaluate these tools’ sensitivity. Here, an
sSNV is considered high quality if it has at least two reads
supporting the alternate allele in disease sample, ≥20 base
quality (Phred), and a minimum 8× coverage.
Figure 1 shows the sensitivity of these tools as a func-
tion of sSNV allele frequencies. Given an allele fre-
quency value f, the sensitivity of a tool T (that is,
JointSNVMix, MuTect, SomaticSniper, Strelka, or VarS-
can 2), is calculated as: ST = NT/Nf, where Nf is the total
number of sSNVs with a frequency less than f, depth ≥8
and the number of alternate allele-supporting reads ≥2
in the disease sample; NT is the number of sSNVs that
the tool T identifies out of these Nf point mutations.
From Figure 1, we can see that MuTect detected more























Figure 1 Sensitivity as a function of mutation allele frequency for five s
a tool T (either JointSNVMix, MuTect, SomaticSniper, Strelka, or VarScan 2) is c
sequencing depth ≥8, the number of alternate allele-supporting reads ≥2 in
number of sSNVs that the tool T identified out of these Nf point mutations.sSNVs at higher allele fractions, VarScan 2 outperformed
MuTect and other tools in its sensitivity ranking, which
is consistent with our previous observation involving
real tumor samples where VarScan 2 was the most sensi-
tive software for detecting high-quality sSNVs.
In order to interrogate ultra-rare sSNVs, for example,
point mutations with frequencies <1/100 or even as low
as 1/10,000 alleles, investigators are advised to utilize
targeted deep sequencing [28-30] instead of WES or
WGS, where the average coverage is relatively low. How-
ever, targeted deep sequencing and related tools are
beyond the scope of this paper, as our focus here is on
tools designed primarily for WGS and WES, which are
currently the most popular technologies for investigating
sSNVs as well as other genetic variations in cancer.
Conclusions
The accurate characterization of sSNVs in tumor-
normal matched samples is critical to cancer research
and personalized cancer therapy. In this paper, we have
evaluated the capability of new sSNV detection tools.
Our discussion focused on MuTect and VarScan 2 in
particular due to their relatively high accuracy [13,15]
and widespread application to NGS-based cancer stud-
ies. Of note, our analysis of their performance on real
tumor samples was restricted to a relatively small data-
set, which included 237 successfully validated sSNVs and
169 false-positive ones.
Our results highlighted the distinct performance of
these sSNV-detecting tools. Although a large number of5 0.3 0.35 0.4 0.45 0.5
equency
SNV-detecting tools. Given an allele frequency value f, the sensitivity of
alculated as: ST = NT/Nf where Nf is the total number of sSNVs with
the disease sample, and an allele frequency less than f, and NT is the
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among these tools, the overall observation across our
three types of benchmark data demonstrated that VarScan
2 excelled at the detection of high-quality sSNVs (high
coverage and allele frequency), while MuTect outper-
formed all other tools in detecting low-quality ones. Their
distinct features hence suggest that a combination of mul-
tiple tools, for example, MuTect with VarScan 2, may
benefit real projects by identifying more sSNVs.
Herein, we also provided an in-depth discussion of the
types of sSNVs that a tool might have missed and the
typical false-positive detections by these tools. Our
evaluation using real tumor sequencing data demon-
strated that in comparison with VarScan 2, MuTect
missed more sSNVs with alternate allele in normal sam-
ples. Moreover, both MuTect and VarScan 2 were flawed
in discerning sSNVs with alternate allele in normal sam-
ple and sSNVs exhibiting strand bias; therefore, we sug-
gest investigators select such sSNVs with caution for
follow-up experimental validation.
We have also examined these sSNV detection tools at
different allele frequencies using simulation data. Our
results showed that MuTect outperformed other tools in
characterizing low allelic-fraction sSNVs. However, exist-
ing tools, including MuTect, all missed the majority of
sSNVs at low allele frequencies on our simulation data.
Thus, to interrogate cancer genomes in exquisite detail,
there is still significant room for improvement.
Additional files
Additional file 1: Tables S1-S3. The somatic single nucleotide variants
(sSNVs) identified using the tools JointSNVMix, MuTect, SomaticSniper,
Strelka, and VarScan 2 from the melanoma sample were provided in
Table S1. The sSNVs identified in the seven lung cancer cell lines were
provided in Table S2. The number of sSNVs detected in the simulation
data was provided in Table S3.
Additional file 2: Simulation of whole exome sequencing.
Additional file 3: Detailed command lines for installing and
running sSNV-detecting tools.
Additional file 4: Figure S1. The number of false-positive sSNVs
identified in 18 lung tumors. In total, 94 sSNVs were validated as false-
positives for this data. Another program, VarScan 2, reported five out of 94
false positive sSNVs, all or most of which were also reported by these four
tools and, hence, were not depicted here so as to make the figure readable.
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